Literature DB >> 33151324

Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer.

Ding Ma1, Si-Yu Chen1,2, Jin-Xiao Ren1,2, Yu-Chen Pei1, Cong-Wei Jiang3, Shen Zhao1, Yi Xiao1, Xiao-En Xu1,2,4, Guang-Yu Liu1,2, Xin Hu1,2, Xiao-Zhen Liang3, Ke-Da Yu1,2, Da-Qiang Li1,2,4, Yi-Zhou Jiang1,2, Zhi-Ming Shao1,2,4.   

Abstract

BACKGROUND: The germline variant spectrum of triple-negative breast cancer (TNBC) is different from that of other subtypes and has demonstrated ethnic differences. However, the germline variants of TNBC among Chinese patients and its clinical significance remain unclear.
METHODS: Using our multi-omics TNBC cohort (n = 325), we determined the spectrum of germline variants in TNBC and aimed to illustrate their biological and clinical implications.
RESULTS: Overall, 16.0% (52 of 325) of TNBC patients harbored at least 1 pathogenic or likely pathogenic germline variant. These germline variants were associated with early onset of TNBC, the occurrence of contralateral breast cancer, the basal-like immune-suppressed mRNA subtype, and the homologous recombination deficiency (HRD) mutation subtype. Somatic allele-specific imbalance was observed in 54.1% of these germline variants, which was correlated with early onset of breast cancer and elevated HRD. The genes BRCA1 (7.4%), RAD51D (2.8%), and BRCA2 (2.2%) were those most frequently mutated. The RAD51D germline variants, especially K91fs, were enriched in Chinese patients with TNBC compared with Caucasian and African American patients. The Chinese-specific RAD51D germline variants were functionally associated with the instability of the RAD51D protein, HRD, and sensitivity to PARP inhibitors.
CONCLUSIONS: Chinese TNBC patients have a distinct spectrum of germline variants, with a remarkable impact on the clinical and molecular characteristics of the tumor. Integrative germline-somatic analysis may help identify TNBC patients who are most likely to be affected by their germline variants and in performing clinical interventions more precisely. The RAD51D variants enriched in our cohort may serve as therapeutic targets and guide precision treatment of TNBC.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33151324     DOI: 10.1093/jnci/djaa175

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

Review 1.  Hypertension in Cancer Survivors.

Authors:  Mohammed Hasan Khan; Surabhi Pathak; Udit Yadav; Yogita Rochlani; Wilbert S Aronow
Journal:  Curr Hypertens Rep       Date:  2022-07-19       Impact factor: 4.592

2.  Prediction of axillary lymph node metastasis in triple-negative breast cancer by multi-omics analysis and an integrated model.

Authors:  Si-Yuan Li; Yu-Wei Li; Ding Ma; Zhi-Ming Shao
Journal:  Ann Transl Med       Date:  2022-06

Review 3.  Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review.

Authors:  Zahra Foruzandeh; Davood Ghavi Dorabadi; Farzaneh Sadeghi; Fatemeh Zeinali-Sehrig; Mohammad Zaefizadeh; Yazdan Rahmati; Mohammad Reza Alivand
Journal:  Mol Biol Rep       Date:  2022-05-10       Impact factor: 2.742

4.  The DNA damage repair landscape in Black women with breast cancer.

Authors:  Aloran Mazumder; Athena Jimenez; Rachel E Ellsworth; Stephen J Freedland; Sophia George; Matthew N Bainbridge; Svasti Haricharan
Journal:  Ther Adv Med Oncol       Date:  2022-02-08       Impact factor: 8.168

Review 5.  Breast cancer screening and early diagnosis in Chinese women.

Authors:  Rui Ding; Yi Xiao; Miao Mo; Ying Zheng; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  Cancer Biol Med       Date:  2022-04-05       Impact factor: 5.347

Review 6.  The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.

Authors:  Guang Yang; Tao Lu; Daniel J Weisenberger; Gangning Liang
Journal:  Genes (Basel)       Date:  2022-08-29       Impact factor: 4.141

7.  Germline Variants in 32 Cancer-Related Genes among 700 Chinese Breast Cancer Patients by Next-Generation Sequencing: A Clinic-Based, Observational Study.

Authors:  Liu Yang; Fei Xie; Chang Liu; Jin Zhao; Taobo Hu; Jinbo Wu; Xiaotao Zhao; Shu Wang
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

8.  The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.

Authors:  Carla Escudeiro; Carla Pinto; Joana Vieira; Ana Peixoto; Pedro Pinto; Manuela Pinheiro; Catarina Santos; Joana Guerra; Susana Lisboa; Rui Santos; João Silva; Conceição Leal; Nuno Coimbra; Paula Lopes; Marco Ferreira; Ana B Sousa; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2020-10-14       Impact factor: 2.375

Review 9.  Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer.

Authors:  Miquel Ensenyat-Mendez; Pere Llinàs-Arias; Javier I J Orozco; Sandra Íñiguez-Muñoz; Matthew P Salomon; Borja Sesé; Maggie L DiNome; Diego M Marzese
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.